Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17

CARLSBAD, Calif., June 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the fourth and last of this series of conference calls focused on the drugs in Isis' development pipeline.  The last call of the series will focus on Isis' neurodegenerative franchise and will be held on Thursday, June 17, 2010 at 12:00 p.m. ET.  This call will be archived for a limited time on Isis' Web site.

Isis has conducted three earlier calls that highlighted its cardiovascular, metabolic and cancer franchises.  The last call of the series will focus on Isis' neurodegenerative franchise as well as some of the other promising programs Isis and its partners are developing.  

Conference Call

At 12:00 p.m. Eastern Time Thursday, June 17, 2010, Isis will conduct a live webcast conference call.  Interested parties may listen to the call by dialing 866-831-6247 and refer to passcode "ISIS 2010" or access the webcast at  A webcast replay will be available for a limited time at the same address.  

Isis' Neurodegenerative Franchise

Isis is pursuing the discovery and development of antisense drugs for neurodegenerative diseases in which there is a large unmet need for new treatment options.  Isis' initial goal is to develop antisense drugs to treat severe diseases with identified genetic causes.  Isis has initiated several programs to develop drugs to treat severe neurodegenerative disease and funded three of these programs in part through grants.  The most advanced program in Isis' neurodegenerative franchise is its SOD1 drug to treat amyotrophic lateral sclerosis, or ALS, also known as Lou Gehrig's disease.  Isis recently added a drug designed to treat spinal muscular atrophy into its development pipeline and is developing novel treatments for other severe neurodegenerative diseases.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' pipeline.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.  

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Vancouver ... lancet that features Owen Mumford,s unique Comfort Zone Technology®. ... Unistik® Touch is a touch activated lancet that features ... Owen Mumford, a leading medical device manufacturer, today unveils ... available initially in the US before expanding out to ...
(Date:12/1/2015)... Dec. 1, 2015 Today the Allen Institute ... Seattle,s South Lake Union neighborhood, the ... Mercer Street and Westlake Avenue North, the 270,000 square ... Institute for Brain Science and the Allen Institute for ... and founder of the Allen Institute. "We started by ...
(Date:12/1/2015)... CAMBRIDGE, Mass. , Dec. 1, 2015 ... and the McGovern Institute for Brain Research at MIT ... system that significantly cut down on "off-target" editing errors. ... issues in the use of genome editing. ... report that changing three of the approximately 1,400 amino ...
(Date:12/1/2015)... -- Twist Bioscience, a company focused on synthetic DNA, today announced ... selected as one of Foreign Policy,s 100 Leading ... of life . Each year, Foreign Policy selects ... have changed lives and are shaping the world. ... to be recognized among these incredible global leaders," said Leproust. ...
Breaking Biology Technology:
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):